Mean case duration before and after intervention (t-statistic = -3.35, p <i>< </i>0.001), indicating a statistically significant difference in means. by Mohammad Bakhtiari (11838264)

Subjects:

The comparison of GCF visfatin level before and three months after NSPT among cases with periodontitis. by Zahra Tajik (20752452)

The comparison of saliva visfatin level before and three months after NSPT among cases with periodontitis. by Zahra Tajik (20752452)

Summary of meta-analysis results to compare visfatin level before and after NSPT among cases with periodontitis. by Zahra Tajik (20752452)

The comparison of GCF visfatin level before and three months after NSPT among cases with periodontitis and T2DM. by Zahra Tajik (20752452)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Summary of meta-analysis results to compare visfatin level before and after NSPT among cases with periodontitis and T2DM. by Zahra Tajik (20752452)

Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. by Ryan J. Treves (13527735)

(A) Auxiliary marking points to ensure complete and accurate seating of the prosthesis. by Long Li (6555)

List of Included studies. by Zahra Tajik (20752452)

“…Sixteen studies were included in the meta-analysis. The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. …”

List of excluded studies. by Zahra Tajik (20752452)

“…Sixteen studies were included in the meta-analysis. The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. …”

Additional file 7 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

Additional file 11 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

Additional file 1 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

Additional file 10 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

Additional file 3 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

Additional file 5 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

A summary of the included study characteristics. by Zahra Tajik (20752452)

“…Sixteen studies were included in the meta-analysis. The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. …”

Differences in mean number of papers (top) and co-authors (bottom) depending on (1) NI membership and (2) time joined NI. by William C. Barley (8915282)

Subjects:

Process model discovered using the cases in top four variants (80%) of the cases according to Pareto Diagram 15A. by Mohammad Bakhtiari (11838264)

Subjects: